Solobacterium moorei sepsis secondary to flexor tenosynovitis: a case report and review of literature
Abstract
ABSTRACT Background Solobacterium moorei is a gram-positive, non-sporulating, strict anaerobic bacillus and an uncommon human pathogen typically found in skin and soft tissue infections. Additionally, S. moorei is a rare cause of severe infections associated with bacteremia. Case Summary We report a case of a 56-year-old African American man with S. moorei bacteremia, likely due to a bite wound, and review 25 previously reported cases. The patient recovered after incision and drainage of flexor tenosynovitis and treatment with 15 days of aminopenicillin/beta-lactamase inhibitor antibiotics. Conclusion S. moorei was identified with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, whereas most other reports used 16s RNA sequencing. Literature review indicates isolates are typically susceptible to penicillins, beta-lactam/beta-lactamase inhibitors, carbapenems, and 3rd/4th-generation cephalosporins but may be resistant to metronidazole, levofloxacin, and rifampin. Improvements in diagnostic methods may lead to more frequent identification of S. moorei in cases of severe sepsis.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.